GeoVax Labs (GOVX) Competitors

GeoVax Labs (NASDAQ:GOVX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership, community ranking and risk.

Is GOVX or PRLD more profitable?

Prelude Therapeutics' return on equity of -66.89% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-809.87%	-349.34%
Prelude Therapeutics	N/A	-66.89%	-55.59%

Do analysts prefer GOVX or PRLD?

GeoVax Labs presently has a consensus price target of $14.20, indicating a potential upside of 1,227.10%. Prelude Therapeutics has a consensus price target of $4.00, indicating a potential upside of 476.37%. Given GeoVax Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe GeoVax Labs is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29
Prelude Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community favor GOVX or PRLD?

Prelude Therapeutics received 4 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 96.43% of users gave GeoVax Labs an outperform vote while only 50.00% of users gave Prelude Therapeutics an outperform vote.

Company	Underperform	Outperform
GeoVax Labs	Outperform Votes 27 96.43%	Underperform Votes 1 3.57%
Prelude Therapeutics	Outperform Votes 31 50.00%	Underperform Votes 31 50.00%

Which has more volatility and risk, GOVX or PRLD?

GeoVax Labs has a beta of 3.7, indicating that its stock price is 270% more volatile than the S&P 500. Comparatively, Prelude Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Which has preferable valuation and earnings, GOVX or PRLD?

GeoVax Labs has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$3.95M	3.74	-$25.97M	-$5.67	-0.19
Prelude Therapeutics	$7M	5.47	-$121.83M	-$1.69	-0.41

Does the media prefer GOVX or PRLD?

In the previous week, GeoVax Labs had 3 more articles in the media than Prelude Therapeutics. MarketBeat recorded 9 mentions for GeoVax Labs and 6 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 0.84 beat GeoVax Labs' score of 0.38 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GeoVax Labs	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in GOVX or PRLD?

6.1% of GeoVax Labs shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 5.7% of GeoVax Labs shares are owned by insiders. Comparatively, 62.8% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

GeoVax Labs and Prelude Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.